Coya Therapeutics, Inc. (COYA) AI Stock Analysis

• Market Cap: $104.38M
• Dividend Yield: N/A
• Average Volume (3M): 266.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: -58.26%
• EPS Growth: -53.20%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 23,457,184
• 10 Day Avg. Volume: 216,274
• 30 Day Avg. Volume: 266,345
• PEG Ratio: -0.15
• Price to Book (P/B): 2.26
• Price to Sales (P/S): 12.21
• P/FCF Ratio: -9.04
• Enterprise Value/Market Cap: 0.26
• Enterprise Value/Revenue: 3.45
• Enterprise Value/Gross Profit: 3.47
• Enterprise Value/Ebitda: -1.36
• 1Y Price Target: $16.25
• Price Target Upside: 265.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -1.49
• Revenue Forecast (FY): $1.92M

• Rating: 51 Neutral
• Price Target: $4.50 ▲(1.12% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held back primarily by persistent losses and ongoing cash burn, alongside weak technical trend signals (below major moving averages with negative MACD). Offsetting factors include a debt-free balance sheet with improved equity and positive corporate developments supporting liquidity and clinical progress.

Positive Factors

Debt-free balance sheet, improving equity

A zero-debt capital structure and materially improved equity provide durable financial flexibility for a clinical-stage biotech. This reduces refinancing and interest-rate risks, preserves optionality for partnerships or asset-centric financings, and supports funding of trials and tech transfer without near-term leverage constraints.

Committed financing and runway into 2H 2027

The combination of an ~$11.1M strategic private placement led by Dr. Reddy’s and an unaudited $46.8M cash balance extends runway through key catalysts. This funding specifically targets manufacturing scale-up for COYA 302, reducing execution risk around commercial readiness and supporting near-term trial completion and data timing.

Clinical proof-of-concept and program milestones

Demonstrated biological activity and favorable safety in an investigator-initiated FTD cohort validates the company’s Treg approach and supports platform de-risking. Positive biomarker and stability signals create a foundation for partnering, downstream development, and rationale for advancing COYA 302 and combination strategies.

Negative Factors

Persistent net losses and weak margins

Consistent net losses and extremely negative margins indicate the company has not achieved scalable economics. Until products reach commercialization or consistent partnership revenue grows, losses will compress returns and require ongoing external funding, limiting self-sustaining growth prospects.

Ongoing negative operating and free cash flow

Stable but persistent cash burn (~$10M yearly) creates a structural funding need. Even with current runway, repeated reliance on milestone payments or financings is likely, increasing dilution risk and constraining long-term R&D prioritization if key trial readouts are delayed or fail to unlock further partner funding.

Small operational scale and revenue reliance on collaborations

With only a handful of employees and no product-sales revenue, the business depends on partnerships, milestone payments, and sporadic licensing income. This narrow operational scale and revenue concentration heighten execution risk and vulnerability to partner decisions or single-trial outcomes.

Coya Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

How the Company Makes Money

COYA is a clinical-stage biotech and does not primarily generate revenue from product sales. Its earnings, when present, are generally expected to come from (1) collaboration and licensing arrangements—such as upfront payments, research and development funding reimbursements, and potential regulatory, development, and commercial milestone payments from partners—and (2) potential future royalties on partner sales if any partnered products reach commercialization. The company may also generate limited other income (e.g., interest income) depending on its cash balance, but detailed breakdowns and the existence/terms of any specific current partnerships, milestone schedules, or royalty structures are null if not publicly disclosed in the requested context.

Coya Therapeutics, Inc. Financial Statement Overview

Summary

Revenue rebounded sharply in 2025, and the company has no reported debt with equity improving from negative (2022) to positive (2023–2025). However, financial results remain dominated by recurring net losses, inconsistent/weak gross profitability, and ongoing negative operating and free cash flow (continued cash burn).

Income Statement

Revenue rebounded sharply in 2025 (annual revenue up ~99% versus 2024), showing improving commercialization/partnering momentum. However, profitability remains weak: the company has posted recurring net losses across all years provided, with very negative net margins (2025 net margin about -267%). Gross profit has also been inconsistent (negative in 2024 and effectively zero/low in other years), indicating limited scale and/or high direct costs relative to revenue.

Balance Sheet

The balance sheet is conservatively levered, with total debt reported at 0 in 2023–2025 and a debt-to-equity ratio of 0, which reduces financial risk. Equity has improved materially from negative in 2022 to positive and growing in 2023–2025, supporting solvency. The key weakness is returns: return on equity is negative in 2023–2025, reflecting continued losses despite a stronger capital base.

Cash Flow

Cash generation remains a clear pressure point: operating cash flow and free cash flow are negative in every year shown, including 2025 (about -$10.7M), indicating ongoing cash burn typical of development-stage biotech. Free cash flow deterioration in 2025 (down ~12% year over year) adds risk. A positive note is that cash burn appears relatively stable in magnitude versus prior years (generally around -$10M to -$11M in 2023–2025), but it still requires funding support until profitability improves.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.95M	3.55M	6.00M	0.00	0.00
Gross Profit	7.92M	-8.31M	500.68K	-4.41M	0.00
EBITDA	-20.24M	-17.20M	-7.33M	-9.26M	-4.85M
Net Income	-21.23M	-14.88M	-7.99M	-12.24M	-4.89M
Balance Sheet
Total Assets	49.95M	44.35M	41.26M	8.40M	4.79M
Cash, Cash Equivalents and Short-Term Investments	46.82M	38.34M	32.63M	5.93M	4.34M
Total Debt	0.00	0.00	0.00	12.97M	0.00
Total Liabilities	6.92M	4.77M	5.63M	16.79M	1.15M
Stockholders Equity	43.03M	39.58M	35.64M	-8.39M	3.64M
Cash Flow
Free Cash Flow	-10.74M	-10.29M	-11.19M	-7.24M	-4.04M
Operating Cash Flow	-10.74M	-10.29M	-11.19M	-7.24M	-3.90M
Investing Cash Flow	-1.16M	-25.00K	-543.19K	-525.00K	-136.80K
Financing Cash Flow	20.39M	16.03M	38.43M	9.36M	-340.58K

Coya Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Negative. The current price of 4.45 is below the 20-day moving average (MA) of 4.77, below the 50-day MA of 4.75, and below the 200-day MA of 5.70, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 39.88 is Neutral, neither overbought nor oversold. The STOCH value of 17.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COYA.

Coya Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COYA	51 Neutral	$104.38M	-4.57	-62.18%	―	-58.26%	-53.20%
STTK	50 Neutral	$432.25M	-7.52	-65.03%	―	-84.46%	33.32%
SPRO	48 Neutral	$138.59M	-3.58	-125.91%	―	-67.38%	-1076.54%
NKTX	47 Neutral	$159.11M	-1.76	-27.69%	―	―	25.84%
INO	45 Neutral	$114.69M	54.17	-353.36%	―	-10.36%	42.36%
ANVS	45 Neutral	$70.04M	-2.46	-159.43%	―	―	62.84%

Coya Therapeutics, Inc. Corporate Events

Coya Therapeutics Announces Strategic Private Placement Financing

On January 29, 2026, Coya Therapeutics, Inc. entered into a securities purchase agreement with Dr. Reddy’s Laboratories and Greenlight Capital for a private placement of 2,522,727 common shares at $4.40 per share, expected to close on or about January 30, 2026 and raise roughly $11.1 million in gross proceeds. The financing, led by a $10 million investment from Dr. Reddy’s, a subsidiary of Coya’s current strategic collaborator, and $1.1 million from existing shareholder Greenlight Capital, is structured as an unregistered offering under Section 4(a)(2), with Coya committing to register the resale of the shares after closing; the company plans to use the funds to transfer and scale up manufacturing of low-dose IL‑2 to support commercial readiness of COYA 302, while reiterating that the additional capital should accelerate its commercial plans without altering its cash runway guidance into the second half of 2027 and beyond the projected topline readout of its ALSTARS ALS trial.

The most recent analyst rating on (COYA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Coya Therapeutics Reports Strong Cash Position and Runway

On January 20, 2026, Coya Therapeutics, Inc. informed stockholders that its unaudited cash balance as of December 31, 2025 stood at $46.8 million, providing a projected cash runway into the second half of 2027 and supporting continued operations and development activities. The company also noted that it expects to deliver topline data from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, a milestone that could be pivotal for its clinical progress and of particular interest to investors and other stakeholders tracking its ALS program.

The most recent analyst rating on (COYA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data

On January 8, 2026, Coya Therapeutics, Inc. reported positive results from an investigator-initiated, open-label proof-of-concept study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with frontotemporal dementia over six months at the Houston Methodist Neurological Institute. The regimen, consisting of subcutaneous CTLA4-Ig and a five-day course of low-dose IL-2 every four weeks for 22 weeks, showed a favorable safety profile with only mild injection-site erythema and no serious adverse events, while demonstrating significantly increased Treg suppressive function, Treg percentages, and associated biomarkers (CD25 and FOXP3) from two weeks through 22 weeks. Cognitive assessments using the Montreal Cognitive Assessment and CDR-FTLD scales showed no significant decline from baseline to week 22, suggesting potential disease stabilization in this small cohort and supporting further exploration of Coya’s Treg-targeted approach in FTD.

The most recent analyst rating on (COYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Coya Therapeutics Receives $4.2M Milestone Payment

On December 16, 2025, Coya Therapeutics, Inc. received a $4.2 million milestone payment under a Development and License Agreement with Dr. Reddy’s Laboratories. This payment was triggered by the dosing of the first patient in the company’s ALSTARS trial, which aims to evaluate COYA 302 for treating ALS. The milestone highlights progress in their ALS treatment efforts and reflects positively on the collaboration between Coya and Dr. Reddy’s Laboratories, marking a significant step forward in advancing its clinical operations.

The most recent analyst rating on (COYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.